New Orleans - Determining the relative risk of a cutaneous drug reaction pattern is vital to determining whether the drug(s) in question can be continued currently or rechallenged in the future,
Derm In The News: September 22-28
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Deuruxolitinib Shows Efficacy in Hair Regrowth, Patient Satisfaction, and Psychosocial Wellbeing in Severe Alopecia Areata
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Melinda Gooderham, MSc, MD, FRCPC: Insights Into Lebrikizumab’s Sustained 3-Year Efficacy
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations